Cargill Wins 2026 BIG Innovation Award
20.1.2026 13:00:00 CET | Business Wire | Press Release
Cargill today announced it has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. Cargill was honored in the Innovative Organizations category, alongside a cohort of 159 companies, products and leaders that are transforming industries through applied innovation and measurable real-world impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120109897/en/
Cargill has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system.
The recognition highlights the breadth and depth of Cargill’s innovation strategy, including the company’s use of automation, robotics, artificial intelligence (AI) and predictive analytics to address interconnected global challenges such as food security, climate change, labor constraints and waste. These capabilities are already delivering measurable outcomes, from the use of CarVe computer vision technology to reduce food waste, to a 30x return on investment (ROI) through Cargill’s Port Optimizer initiative, more than $15 million in documented benefits from manufacturing analytics and a reduction of 31,500 metric tons of CO₂ emissions due to vessel optimization and energy-saving upgrades in 2024.
“Innovation at Cargill is not just about what’s next — it’s about what’s needed,” said Florian Schattenmann, chief technology officer at Cargill. “By embedding AI and advanced analytics in our operations, we are reimagining the way food is made and moved across the globe. This recognition reflects the ingenuity of our teams and the power of innovation to build a more resilient and efficient food system for the future.”
BIG Innovation Award judges praised Cargill’s work as “serious, large-scale innovation executed with discipline, embedded deeply into real operations.” They also commended the company for a comprehensive approach that spans multiple technologies and business lines and is backed by robust data and outcomes.
"The 2026 BIG Innovation Awards winners show that true innovation is no longer about chasing the latest buzzwords," said Russ Fordyce, Chief Recognition Officer at the Business Intelligence Group. "It’s about building intelligent platforms, automating workflows with purpose, and making trust, privacy, and resilience the foundation of every breakthrough. These organizations and leaders are not just keeping pace with change, they are shaping the future of global business."
The 2026 BIG Innovation Awards program honors companies, products and individuals that are reshaping markets across sectors ranging from health and financial services to logistics, manufacturing and enterprise technology. Winning organizations were selected by a panel of experienced business executives, who evaluated nominations based on measurable performance, responsible implementation and the ability to shape the future of work and culture.
For more information about the BIG Innovation Awards and to view the full list of winners, visit www.bintelligence.com/posts/2026-big-innovation-awards-159-trailblazers-prove-where-innovation-is-really-happening.
About Cargill
Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.
Our 155K+ employees innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 160 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.
About Business Intelligence Group
The Business Intelligence Group was founded with the mission of recognizing true talent and superior performance in business. Unlike many recognition programs, these awards are evaluated by business leaders and practitioners who reward programs, products, and people that deliver real, quantifiable excellence rather than marketing narratives.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260120109897/en/
Contacts
Media Contact:media@cargill.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 07:00:00 CET | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 07:00:00 CET | Press Release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 07:00:00 CET | Press Release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 07:00:00 CET | Press Release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Completes Successful Placement of EUR 500 Million Eurobond11.3.2026 06:55:00 CET | Press Release
Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION. Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%. The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange. Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction. Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings. Galderma is currently rated ‘BBB’ (stable outlook) by Fitc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom